Printer Friendly

A Review of UCB Pharma Including Their 14 Deals Made, 19 Partnering Companies, and Financial Information.

DUBLIN, Ireland -- Research and Markets ( ) has announced the addition of UCB Pharma Deals Briefing to their offering.


UCB Pharma Deals briefing provides an in-depth view of the 14 deals made by UCB Pharma with 19 partnering companies between 2000 and 2005, in a clear and accessible PDF format.

Chapter 1: Company profile

An overview of the company, including contact details, a summary of business and partnering interests, and a review of management

Chapter 2: Financial data and deals overview

A summary of the company's financial status and overview of the numbers of deals by deal type, therapy focus, deal stage and industry sector.

Chapter 3: Summary of deals

A comprehensive overview listing deals by partner company, therapy focus and development stage, with a full index of all the deals announced.

Chapter 4: List of deals

A detailed listing of all the company's deals and alliances announced between January 2000 and July 2005.

Every deal is fully categorized, includes a detailed description, and includes financials such as headline value, upfront payments and royalty rates, where disclosed.


The report contains:

a brief company profile

financial information where disclosed

a deals overview

specialized indexes including deals by partner company, subsidiary company, therapy focus and development stage

a detailed listing of the company's deals and alliances.

Key questions answered

UCB Pharma Deals briefing provides a comprehensive summary of the deals and alliances announced by the company between January 2000 and July 2005. This report helps in:

identifying active partners

tracking competitor activity

benchmarking deals

comparing the finances of different deal types.

UCB Pharma Deals briefing brings all relevant partnering deals into one place, providing a reference to deal making by UCB Pharma.

Forecasts, projections, market estimates

This report provides: a financial summary table detailing the yearly total revenues, pharma revenues, R&D spend and profit of the company; and a series of tables detailing the number of deals made by deal type, by therapy focus, by development stage and by industry sector.

Who should buy the report

This report is essential reading for board and executive management, and individuals in:

business development


deal making

business strategy

marketing and promotion

distribution and manufacturing (including contract services).

Topics Covered


About Partneringdesk Deals briefings

Chapter 1: Company profile

Chapter 2: Financial data and deals overview

Chapter 3: Summary of deals

Deals involving UCB Pharma by partner company

Deals involving UCB Pharma by subsidiary

Deals involving UCB Pharma by therapy focus

Deals involving UCB Pharma by development stage

Chapter 4: List of deals


List of Tables

Table 2.1 UCB Pharma financial summary

Table 2.2 UCB Pharma deals by deal type

Table 2.3 UCB Pharma deals by therapy focus

Table 2.4 UCB Pharma deals by development stage

Table 2.5 UCB Pharma deals by industry sector

For more information visit
COPYRIGHT 2005 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Nov 22, 2005
Previous Article:TTTech and HiRain Form Partnership to Satisfy Demand for TTP-Based Products in China.
Next Article:A Company Analysis of Yamanouchi Pharmaceutical Co Ltd Offering Information about Their Deals Made, Partnering Companies, and Financial Information.

Related Articles
Gene Logic and UCB Pharma Announce Business Expansion.
UCB and Axiom Extend Collaboration in Drug Discovery.
Orders issued under Bank Holding Company Act. (Legal Developments).
A Company Analysis of Purdue Pharma Lp Including Financial Information, Deals Made, and Partnering Companies.
Windhover Information's 16th Annual Pharmaceutical Strategic Alliances Conference ``Externalization: Opportunities, Threats...and New Models THE MOST...
Get Valuable Insights into Biopharma Deal Making with New Report.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters